New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
09:02 EDTACTGAcacia reaches settlement with Mallinckrodt over Exalgo
Actavis announced that it has reached a settlement with Mallinckrodt on outstanding patent litigation related to Actavis' generic version of the 32 mg dosage strength of Mallinckrodt's Exalgo tablets. In January of 2012, Actavis and Mallinckrodt previously settled litigation involving the 8 mg, 12 mg and 16 mg dosage strengths of the product. Under terms of the settlement agreement, Mallinckrodt has granted Actavis a royalty-free license to U.S. patents relating to Exalgo to sell Actavis' 32 mg product starting on May 15, 2014. Other details of the settlement were not disclosed.
News For ACTG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
06:00 EDTACTGAcacia Research enters into settlement, release agreement with Axiom
Acacia Research announced that its Parallel Separation Innovations subsidiary entered into a Settlement and Release Agreement with Axiom Process, and Axiom Process . The agreement resolved litigation that was pending in the United States District Court for the Eastern District of Texas.
November 19, 2014
06:00 EDTACTGAcacia Research signs settlement and patent license agreement with NEC Corp
Subscribe for More Information
November 17, 2014
06:11 EDTACTGAcacia Research subsidiary enters into settlement with Epsilon Data Management
Acacia Research announced that its Online News Link subsidiary has entered into a settlement with Epsilon Data Management. The agreement resolves litigation that was pending in the United States District Court for the Northern District of Texas, Dallas Division.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use